CD33 Specific Neutra™ Antibody Products
Product listCD33 is a protein phosphatase located on several cellular components such as external side of plasma membrane and Golgi apparatus, which is essentially a sialic acid-binding immunoglobulin-like lectin (Siglec) and alias as Siglec3. CD33 regulates monocyte negative activation, protein tyrosine phosphatase positive activity, and cytokine negative production.
Its Gene ID: 945, UniProtKB ID: P20138, and OMIM ID: 159590.
Pathways CD33 Involved in
Siglec3, a CD33-related Siglec protein, exhibits intricate expression patterns within the human and murine immune systems. The majority of CD33-related Siglecs possess single or multiple cytosolic immunoreceptor tyrosine-based inhibitory motifs (ITIMs), crucial components of coherence receptors that hinder activation signals stemming from receptors containing immunoreceptor tyrosine-based activation motifs (ITAMs). Interaction between CD33-related Siglecs and various pathogens is observed, with sialylated pathogens modulating leukocyte activation through ITIM-mediated signaling. This interaction benefits the pathogen by suppressing inflammatory and immune responses, highlighting the complex regulatory role of CD33-related Siglecs in host-pathogen interactions.
Fig.1 Siglec-3/CD33 interacts with human HBV schematic diagram.1
CD33 plays a crucial role in immune response pathways, as evidenced by the interaction between HBV surface antigen and human CD33 confirmed through immunoprecipitation and ELISA. Activation of siglec-3 on myeloid cells by HBV induces immunosuppression through the stimulation of immunoreceptor ITIM phosphorylation and recruitment of SHP-1/-2 via α2,6-biantennary sialoglycans on the HBV surface antigen. This enables multiple-valence binding between the HBV virion and myeloid cells, leading to cross-linking of siglec-3 and initiation of downstream signaling cascades. Creative Biolabs provides Recombinant Anti-CD33 Antibody (V3S-1022-YC589) for your ELISA experiment, and Recombinant Anti-CD33 Antibody (V3S-0522-YC1496) for your immunoprecipitation experiment.
Antibodies of CD33 in Cancer Therapeutics
CD33/Siglec-3 is a member of the Siglecs family, which is gaining prominence as therapeutic targets for addressing cancers and inflammatory, immune disorders. This is attributed to their capacity to modulate cell signaling pathways and their distinctive expression patterns on immune cells.
- Anti-CD33 Antibody Therapies for Myeloid Hematologic Malignancies
CD33 acts as an AML tumor-associated antigen and is at the forefront of targeted therapy development, which is expressed on a subset of cases of non-myeloid hematologic malignancies, including some mature T cell malignancies, mast cell neoplasms and acute lymphoblastic leukemia of T and B cell lineage. Recent research shows that a Fc-engineered CD33 antibody and bispecific antibodies targeting CD33 and engaging T cells and NK cells have demonstrated efficacy in eliminating putative myeloid-derived suppressor cells (MDSCs) derived from high-risk myelodysplastic syndrome patients. These findings highlight the ability of these antibodies to reverse immune suppression induced by MDSCs.
Additionally, in the realm of AML therapy research, Creative Biolabs presents the Recombinant Anti-CD33 (ECD domain) Neutralizing Antibody (V3S-0622-YC77). This antibody is tailored to specifically impede the growth of CD33-positive leukemia cell lines, including HL-60 and Kasumi-1, offering a specialized tool for your research endeavors.
Fig.2 Functional role of anti-CD33 antibodies in AML therapy.2
- Therapeutic Potential of CD33 Antibodies in Alzheimer's Disease
A SNP in the proximal promoter of CD33 has been associated with susceptibility for Alzheimer's disease. A hypothesized direct involvement of CD33 in the pathogenesis of Alzheimer's disease is supported by evidence published recently indicating that CD33FL diminishes the uptake and clearance of toxic amyloid β species by microglial cells. This effect may take place through the inhibition of activating receptors crucial for microglial phagocytosis. Consequently, anti-CD33 antibodies have the potential to block CD33 function, and enhancing microglial activity in combating Alzheimer's disease.
Fig.3 The involvement of Siglec in mediating microglial functions through CD33.3
Creative Biolabs provides a diverse range of >50 recombinantly expressed anti-CD33 antibody products. These antibodies are applicable for research in therapies targeting AML, Alzheimer's disease, and various other disorders. Our esteemed customers can also get customization products for CD33-based bispecific antibodies.
REFERENCES
- Tsai, Tsung-Yu, et al. "SIGLEC-3 (CD33) serves as an immune checkpoint receptor for HBV infection." The Journal of clinical investigation 131.11 (2021).
- Williams, Brent A., et al. "Antibody therapies for acute myeloid leukemia: unconjugated, toxin-conjugated, radio-conjugated and multivalent formats." Journal of clinical medicine 8.8 (2019): 1261.
- Rawal, Punam, and Liqin Zhao. "Sialometabolism in brain health and Alzheimer's disease." Frontiers in Neuroscience 15 (2021): 648617.
